PE20160840A1 - Formas cristalinas de compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) - Google Patents
Formas cristalinas de compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2)Info
- Publication number
- PE20160840A1 PE20160840A1 PE2016000214A PE2016000214A PE20160840A1 PE 20160840 A1 PE20160840 A1 PE 20160840A1 PE 2016000214 A PE2016000214 A PE 2016000214A PE 2016000214 A PE2016000214 A PE 2016000214A PE 20160840 A1 PE20160840 A1 PE 20160840A1
- Authority
- PE
- Peru
- Prior art keywords
- amino
- idh2
- crystalline forms
- trifluoromethyl
- inhibiting compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 title 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 abstract 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 2
- 239000000428 dust Substances 0.000 abstract 2
- 101710088194 Dehydrogenase Proteins 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 abstract 1
- -1 TRIFLUORomethyl Chemical group 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 229940126214 compound 3 Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A FORMAS CRISTALINAS DE LOS COMPUESTOS METASULFONATO DE 2-METIL-1-[(4-[6-(TRIFLUOROMETIL)PIRIDIN-2-IL]-6-{[2-(TRIFLUOROMETIL)PIRIDIN-4-IL]AMINO}-1,3,5-TRIAZIN-2-IL)AMINO]PROPAN-2-OL (COMPUESTO 1) Y 2-METIL-1-[(4-[6-(TRIFLUOROMETIL)PIRIDIN-2-IL]-6-{[2-(TRIFLUOROMETIL)PIRIDIN-4-IL]AMINO}-1,3,5-TRIAZIN-2-IL)AMINO]PROPAN-2-OL (COMPUESTO 3) TALES COMO A) LA FORMA 16 CUYO PATRON DE DIFRACCION CON POLVO POR RAYOS X TIENE PICOS EN LOS ANGULOS 2THETA DE 6.8, 10.6, 13.6, 14.2 Y 19.2 ± 0.2°; B) LA FORMA 3 CUYO PATRON DE DIFRACCION CON POLVO POR RAYOS X TIENE PICOS EN LOS ANGULOS 2THETA DE 7.5, 9.3, 14.5, 18.8, 21.3 Y 24.8 ± 0.2°; ENTRE OTROS. DICHOS COMPUESTOS ACTUAN COMO INHIBIDORES DE UN ALELO MUTANTE DE LA ISOCITRATO DESHIDROGENASA 2 (NADP+) MITOCONDRIAL (IDH2) SIENDO UTILES PARA EL TRATAMIENTO DE LEUCEMIA MIELOGENA AGUDA, SINDROME MIELODISPLASICO, LINFOMA
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361861884P | 2013-08-02 | 2013-08-02 | |
| PCT/CN2013/081170 WO2015018060A1 (en) | 2013-08-09 | 2013-08-09 | Crystalline forms of therapeutically active compounds and use thereof |
| US201461939098P | 2014-02-12 | 2014-02-12 | |
| US201461975448P | 2014-04-04 | 2014-04-04 | |
| US201462011948P | 2014-06-13 | 2014-06-13 | |
| PCT/US2014/049469 WO2015017821A2 (en) | 2013-08-02 | 2014-08-01 | Therapeutically active compounds and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160840A1 true PE20160840A1 (es) | 2016-09-22 |
Family
ID=52432592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000214A PE20160840A1 (es) | 2013-08-02 | 2014-08-01 | Formas cristalinas de compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9738625B2 (es) |
| EP (3) | EP3027193A4 (es) |
| JP (3) | JP6742905B2 (es) |
| CN (3) | CN110386922A (es) |
| AU (2) | AU2014295938B2 (es) |
| BR (1) | BR112016002287A2 (es) |
| CA (1) | CA2919382A1 (es) |
| CL (2) | CL2016000263A1 (es) |
| EA (1) | EA030428B1 (es) |
| ES (1) | ES2886211T3 (es) |
| IL (2) | IL243833A0 (es) |
| MX (2) | MX394658B (es) |
| MY (1) | MY177994A (es) |
| NI (1) | NI201600022A (es) |
| PE (1) | PE20160840A1 (es) |
| PH (1) | PH12016500164B1 (es) |
| SA (1) | SA516370523B1 (es) |
| SG (2) | SG11201600479WA (es) |
| TW (2) | TWI666208B (es) |
| UA (1) | UA121021C2 (es) |
| WO (1) | WO2015017821A2 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| SG11201600479WA (en) | 2013-08-02 | 2016-02-26 | Agios Pharmaceuticals Inc | Therapeutically active compounds and their methods of use |
| WO2016053850A1 (en) * | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3253746A1 (en) | 2015-02-04 | 2017-12-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2016177347A1 (en) * | 2015-05-07 | 2016-11-10 | Teligene Ltd | Heterocyclic compounds as idh2 inhibitors |
| US10745383B2 (en) * | 2015-07-30 | 2020-08-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1,3,5-triazine derivative and method of using same |
| JP6816106B2 (ja) | 2015-08-05 | 2021-01-20 | アジオス ファーマシューティカルズ， インコーポレイテッド | ６−ピリジル−１，３，５−トリアジン−２，４−ジオール及び６−ピリジル−１，３，５−トリアジン−２，４−ジアミンを調製する方法 |
| EP4147692A1 (en) * | 2015-10-15 | 2023-03-15 | Les Laboratoires Servier | Combination therapy for treating malignancies |
| ES2862730T3 (es) * | 2015-10-15 | 2021-10-07 | Celgene Corp | Combinación de un inhibidor de isocitrato deshidrogenasa 2 mutante con azacitidina y su uso para el tratamiento de la leucemia mielógena aguda |
| CA3002531C (en) * | 2015-10-21 | 2020-08-18 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof |
| MX391229B (es) * | 2015-12-04 | 2025-03-21 | Agios Pharmaceuticals Inc | Metodos de tratamiento de neoplasias malignas. |
| WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
| AU2016393870B2 (en) | 2016-02-26 | 2023-01-19 | Celgene Corporation | IDH1 inhibitors for the treatment of haematological malignancies and solid tumours |
| EP3493809B1 (en) | 2016-08-03 | 2023-08-23 | Celgene Corporation | Enasidenib for treatment of myelodysplastic syndrome |
| JP7093764B2 (ja) * | 2016-08-03 | 2022-06-30 | セルジーン コーポレイション | 骨髄異形成症候群の治療方法 |
| KR102498693B1 (ko) | 2016-09-07 | 2023-02-10 | 셀진 코포레이션 | 정제 조성물 |
| KR102601722B1 (ko) * | 2017-01-22 | 2023-11-13 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 1,3,5-트리아진 유도체 염, 결정, 제조 방법, 약학적 조성물 및 그의 용도 |
| US11229653B2 (en) | 2017-05-05 | 2022-01-25 | Celgene Corporation | Methods of treatment of myeloproliferative neoplasm |
| LT3644999T (lt) | 2017-06-30 | 2023-03-10 | Celgene Corporation | 2-(4-chlorfenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il) metil)-2,2-difluoracetamido kompozicijos ir panaudojimo būdai |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| US20220017489A1 (en) | 2018-11-02 | 2022-01-20 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| US20220401450A1 (en) | 2019-11-14 | 2022-12-22 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| CN114773320A (zh) * | 2022-05-29 | 2022-07-22 | 重庆医科大学 | 1,3,5-三嗪化合物及其制备方法和用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2390529A (en) | 1942-02-03 | 1945-12-11 | Ernst A H Friedheim | Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds |
| JPS58186682A (ja) | 1982-04-27 | 1983-10-31 | 日本化薬株式会社 | セルロ−ス又はセルロ−ス含有繊維材料の染色法 |
| DE3512630A1 (de) | 1985-04-06 | 1986-10-23 | Hoechst Ag, 6230 Frankfurt | Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern |
| EP0466647B1 (de) | 1990-07-12 | 1995-11-29 | Ciba-Geigy Ag | Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien |
| JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| WO2000075129A1 (en) | 1999-06-07 | 2000-12-14 | Shire Biochem Inc. | Thiophene integrin inhibitors |
| US7291616B2 (en) * | 2001-10-31 | 2007-11-06 | Cell Therapeutics, Inc. | Aryl triazines as LPAAT-β inhibitors and uses thereof |
| ES2392426T3 (es) | 2002-07-18 | 2012-12-10 | Janssen Pharmaceutica Nv | Inhibidores de quinasas con triazina sustituida |
| CN101679321B (zh) | 2007-04-30 | 2012-10-03 | 普罗米蒂克生物科学公司 | 三嗪衍生物、含所述衍生物的组合物以及所述衍生物在制备用于治疗癌症和自身免疫性疾病药物中的应用 |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| CA2764785C (en) | 2009-06-08 | 2015-10-27 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
| US8486939B2 (en) * | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| EP3984997B1 (en) * | 2012-01-06 | 2025-07-30 | Les Laboratoires Servier | Therapeutically active compounds and their methods of use |
| EP2824099A4 (en) | 2012-03-09 | 2015-11-11 | Carna Biosciences Inc | NOVEL TRIAZINE DERIVATIVE |
| CN105492435B (zh) | 2013-07-11 | 2018-06-29 | 安吉奥斯医药品有限公司 | 作为idh2突变体抑制剂的化合物 |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| SG11201600479WA (en) * | 2013-08-02 | 2016-02-26 | Agios Pharmaceuticals Inc | Therapeutically active compounds and their methods of use |
| WO2016053850A1 (en) * | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3253746A1 (en) | 2015-02-04 | 2017-12-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
-
2014
- 2014-08-01 SG SG11201600479WA patent/SG11201600479WA/en unknown
- 2014-08-01 CN CN201910708167.6A patent/CN110386922A/zh active Pending
- 2014-08-01 US US14/909,451 patent/US9738625B2/en active Active
- 2014-08-01 UA UAA201601999A patent/UA121021C2/uk unknown
- 2014-08-01 CA CA2919382A patent/CA2919382A1/en not_active Abandoned
- 2014-08-01 EP EP14832505.3A patent/EP3027193A4/en not_active Withdrawn
- 2014-08-01 AU AU2014295938A patent/AU2014295938B2/en active Active
- 2014-08-01 PE PE2016000214A patent/PE20160840A1/es not_active Application Discontinuation
- 2014-08-01 JP JP2016531940A patent/JP6742905B2/ja active Active
- 2014-08-01 EA EA201690322A patent/EA030428B1/ru not_active IP Right Cessation
- 2014-08-01 WO PCT/US2014/049469 patent/WO2015017821A2/en not_active Ceased
- 2014-08-01 CN CN201480053796.5A patent/CN105916507A/zh active Pending
- 2014-08-01 TW TW103126335A patent/TWI666208B/zh active
- 2014-08-01 EP EP19177845.5A patent/EP3566706B1/en active Active
- 2014-08-01 MY MYPI2016700311A patent/MY177994A/en unknown
- 2014-08-01 CN CN201910707312.9A patent/CN110372670B/zh active Active
- 2014-08-01 EP EP21178745.2A patent/EP3932408A1/en not_active Withdrawn
- 2014-08-01 MX MX2020011397A patent/MX394658B/es unknown
- 2014-08-01 TW TW108110624A patent/TWI701242B/zh active
- 2014-08-01 PH PH1/2016/500164A patent/PH12016500164B1/en unknown
- 2014-08-01 MX MX2016001361A patent/MX389250B/es unknown
- 2014-08-01 ES ES19177845T patent/ES2886211T3/es active Active
- 2014-08-01 SG SG10201709187TA patent/SG10201709187TA/en unknown
- 2014-08-01 BR BR112016002287A patent/BR112016002287A2/pt not_active Application Discontinuation
-
2016
- 2016-01-28 IL IL243833A patent/IL243833A0/en unknown
- 2016-02-01 SA SA516370523A patent/SA516370523B1/ar unknown
- 2016-02-01 NI NI201600022A patent/NI201600022A/es unknown
- 2016-02-02 CL CL2016000263A patent/CL2016000263A1/es unknown
-
2017
- 2017-07-13 US US15/649,551 patent/US10093654B2/en active Active
- 2017-09-04 CL CL2017002240A patent/CL2017002240A1/es unknown
-
2018
- 2018-09-04 US US16/121,483 patent/US10730854B2/en active Active
- 2018-10-10 AU AU2018247242A patent/AU2018247242B2/en active Active
-
2019
- 2019-04-24 JP JP2019082794A patent/JP2019142930A/ja not_active Withdrawn
- 2019-10-31 IL IL270347A patent/IL270347B/en unknown
-
2020
- 2020-06-29 US US16/915,936 patent/US20210155603A1/en not_active Abandoned
-
2021
- 2021-07-29 JP JP2021123814A patent/JP2021176893A/ja active Pending
-
2023
- 2023-05-08 US US18/144,695 patent/US20240132474A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160840A1 (es) | Formas cristalinas de compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) | |
| CL2019000542A1 (es) | Compuestos de tetraciclina y métodos de uso de los mismos. | |
| MX389825B (es) | Compuestos y composiciones para tratar trastornos hematologicos. | |
| PH12016501388A1 (en) | Heteroaryls and uses thereof | |
| CL2015001377A1 (es) | Inhbibidores de bmi-1 primidinas sustituidas inversas | |
| PE20171105A1 (es) | Formas solidas de un inhibidor ask1 | |
| CR20160099A (es) | Formulación de inhibidores de la syk | |
| CL2014002301A1 (es) | Compuestos derivados de pirimidin piridinas sustituidas, inhibidores de serina/treonina cinasas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento de una enfermedad hiperproliferativa tal como melanoma, cancer, leucemias y una enfermedad inflamatoria como artritis y reumatismo entre otras. | |
| NZ715738A (en) | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer | |
| CL2016001368A1 (es) | Inhibidores de cinasa serina/treonina | |
| PH12016501007A1 (en) | Substituted benzamides and methods of use thereof | |
| MX390189B (es) | COMPUESTOS Y METODOS PARA LA DEGRADACION DIRIGIDA DE RECEPTOR DE ANDROGENOs. | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| EA201690473A1 (ru) | Комбинированный состав двух противовирусных соединений | |
| MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
| CR20150667S (es) | Portador, bandeja, abrazadera y perilla | |
| MD20160053A2 (ro) | Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative | |
| CL2016001349A1 (es) | Uso de derivados de bencimidazol-prolina | |
| CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
| MX2016003196A (es) | Derivados antibacterianos del 2h-indazol. | |
| UY34882A (es) | Profármacos de rebamipida novedosos,método para prepararlos y uso de ellos | |
| EA201691566A1 (ru) | Применение производных пиридазина для предупреждения или лечения атаксического синдрома | |
| CL2017002960A1 (es) | Compuesto para la profilaxis o el tratamiento de daño al órgano | |
| NZ710600A (en) | Solid state forms of a quinazoline derivative and its use as a braf inhibitor | |
| CL2016001623A1 (es) | Compuestos de benzamida y nicotinamida y métodos para usar los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |